Lori Anne Kunkel - 20 May 2024 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Role
Director
Signature
/s/ Daniel Burbach, as Attorney-in-Fact for Lori Ann Kunkel
Issuer symbol
NRIX
Transactions as of
20 May 2024
Net transactions value
$0
Form type
4
Filing time
20 May 2024, 19:26:08 UTC
Previous filing
10 Apr 2024
Next filing
04 Jun 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NRIX Director Stock Option (right to buy) Award $0 +25,000 $0.000000 25,000 20 May 2024 Common Stock 25,000 $16.19 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 20, 2025, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.